by
Barbara Kram, Editor | December 26, 2006
“With this imaging biomarker, we may not only have better early diagnosis of the disease but also the possibility of treating people to delay the onset of symptoms,” said Dr. Gary Small, researcher, professor of psychiatry and biobehavioral sciences, UCLA, and co-inventor of the biomarker.
“Our goal is to catch the disease in its earliest stages. If the technology proves successful in clinical trials, it could enable us to test new therapies and develop better drugs to manage the progression of the disease over time. It is clearly easier to protect a healthy brain than repair one that is already damaged.”
Ad Statistics
Times Displayed: 19090
Times Visited: 362 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
“Siemens’ clear objective is to move toward researching the causes of disease, rather than just managing the resulting conditions,” said Michael Reitermann, president, Molecular Imaging Division, Siemens Medical Solutions. “By aiding in the detection of diseases at much earlier stages, new imaging biomarkers may ultimately lead toward more personalized medicine.”
With imaging biomarkers, Siemens is actively researching and investing in technologies that may support a more personalized approach to medicine. After the Phase I study, depending on its outcome, the company will initiate a larger multi-center clinical trial.
Siemens Medical Solutions of Siemens AG (NYSE: SI) is one of the world’s largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics – such as Diagnostic Products Corporation – mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing approximately 36,000 people worldwide and operating in more than 130 countries, Siemens Medical Solutions reported sales of 8.23 billion EUR, orders of 9.33 billion EUR and group profit of 1.06 billion EUR for fiscal 2006 (preliminary figures). Further information can be found by visiting www.usa.siemens.com/medical-pressroom.
Back to HCB News
